When was Inventprise founded?

Inventprise was founded in 2012 and raised its 1st funding round 9 years after it was founded.

Where is Inventprise located?

Inventprise is headquartered in Redmond, United States. It is registered at Redmond, Washington.

How many employees does Inventprise have?

As of Aug 31, 2026, the latest employee count at Inventprise is 90.

Is Inventprise a funded company?

Inventprise is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2021.

When was the latest funding round of Inventprise?

Inventprise's latest funding was a $***** Conventional Debt round on Nov 15, 2021, with participation from 0 investor.

Where does Inventprise rank among its competitors?

Inventprise ranks 75th amongst 197 active competitors, of which 47 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of Inventprise?

Inventprise's top competitors include Vaxart, Insmed and Evofem. Among them, Basilea secured the most recent funding round in May, 2026.

Inventprise - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of conjugate vaccines designed to prevent infectious diseases globally. The company’s platform technologies enable high valent vaccines to induce broad and durable protection against pathogenic strains. The company has a pipeline of investigational vaccines including candidates to prevent group B streptococcus, Shigella, and Klebsiella. The company focuses on vaccine technology, science, and manufacturing to prevent infectious disease.

Website: inventprise.com
Social
Email ID: *****@inventprise.com
Phone Number: +1 **********
Registered Address: Redmond, Washington

Key Metrics

Founded Year

2012

Location

Redmond, United States

Stage

Seed

Latest Funding Round

Conventional Debt, Nov 15, 2021, $*****

Investors

Gates & 1 more

Ranked

75^th among 197 active competitors

Employee Count

90 as on Aug 31, 2026

Similar Companies

Vaxart & 120 more

View Inventprise's full profile

Inventprise is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Inventprise, Llc CIN: 454927373 , United States, Active	Dec 26, 999	-	165 (As on Dec 31, 2024)	-

Inventprise has raised funding over 2 rounds. Its first funding round was on 2021. Inventprise has 2 institutional investors.

Here is the list of recent funding rounds of Inventprise:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 15, 2021	9447399	Conventional Debt	4036147	6014915	2673159	4203716
2021	3834	Seed	4270	9477	4104	Gates

Access funding benchmarks and valuations. Sign up today!

View details of Inventprise's funding rounds and investors

The founders of Inventprise is Subhash Kapre. Yves Leurquin is the CEO of Inventprise.

Here are the details of Inventprise's key team members:

Subhash Kapre: Founder of Inventprise.
Contact Info: 1 email address
Yves Leurquin: CEO of Inventprise.
Contact Info: 1 email address

View details of Inventprise's Founder profiles and Board Members

Inventprise's employee count trend

Inventprise has 90 employees as of Aug 26. Here is Inventprise's employee count trend over the years:

Uncover Inventprise's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Inventprise include Vaxart, Insmed and Evofem. Here is the list of Top 10 competitors of Inventprise, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	67/100
2nd	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Foresite Capital, Quaker Partners Management ... & 13 others	66/100
3rd	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	mercerstcap.com, Aditx Therapeutics & 10 others	61/100
4th	SNIPR Biome 2011, Copenhagen (Denmark), Series B	Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely	$139M	Lundbeck Foundation, Life Sciences Partners ... & 7 others	61/100
5th	SpyBiotech 2017, Oxford (United Kingdom), Series A	Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology	$39M	Braavos, Oxford Science Enterprises & 6 others	61/100
6th	Affinivax 2013, Cambridge (United States), Acquired	Developer of technology-based conjugate vaccines against infectious diseases	$359M	Gates, Foresite Capital & 14 others	59/100
7th	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
8th	TuHURA Biosciences 1996, Tampa (United States), Public	Developer of immunotherapies for the treatment of cancer	$41.5M	HHS, Valirx & 1 others	58/100
9th	Centauri Therapeutics 2014, Kent (United Kingdom), Series A	Developer of immunotherapeutics to treat infectious diseases	$73M	REPAIR Impact Fund, Boehringer Ingelheim Venture Fund ... & 32 others	58/100
10th	CanSino Biologics 2009, Tianjin (China), Public	Developer of vaccines for the treatment of infectious diseases	$105M	SDIC Innovation, Lilly Asia Ventures & 9 others	56/100
75th	Inventprise 2012, Redmond (United States), Seed	Developer of conjugate vaccines designed to prevent infectious diseases globally	-	Gates & 1 others	35/100